-
Novel drug candidates for pain
and central nervous system diseasesGlobal
more details
PIPELINE - Opiranserin (VVZ-149) injection is a first-in-class non-narcotic analgesic under development by Vivozon. Vivozon is expanding its target combination of second-generation analgesic drug candidates and striving to expand its pipeline across the central nervous system disease field. more details
-
Core competencies for success
Chemistry,
more details
Biology,
Clinical. - Vivozon develops new chemical drugs that act on multi-targets to create synergistic efficacy. By applying efficacy-based screening from the early stage of discovery, we derive candidate substances with high potential for successful phase 2 clinical trials and continue with global clinical development. more details
Vivozon is at the forefront of the road to the future of humanity